


Status: Currently Official on 17-Feb-2025  
 Official Date: Official as of 01-Jan-2018  
 Document Type: USP Monographs  
 DocId: GUID-EDB9A773-95A7-4E92-8F82-437A1707729C\_3\_en-US  
 DOI: [https://doi.org/10.31003/USPNF\\_M82870\\_03\\_01](https://doi.org/10.31003/USPNF_M82870_03_01)  
 DOI Ref: dxf11

© 2025 USPC  
 Do not distribute

## Thiopental Sodium



$C_{11}H_{17}N_2NaO_2S$  264.32

4,6(1*H*,5*H*)-Pyrimidinedione, 5-ethyldihydro-5-(1-methylbutyl)-2-thio-, monosodium salt, (±)-;

Sodium (±)-5-ethyl-5-(1-methylbutyl)-2-thiobarbiturate CAS RN®: 71-73-8; UNII: 49Y44QZL70.

### DEFINITION

Thiopental Sodium contains NLT 97.0% and NMT 102.0% of thiopental sodium ( $C_{11}H_{17}N_2NaO_2S$ ), calculated on the dried basis.

### IDENTIFICATION

#### • A.

**Sample:** 500 mg of Thiopental Sodium

**Analysis:** Dissolve the *Sample* in 10 mL of water in a separator, add 10 mL of 3 N hydrochloric acid, and extract the liberated thiopental with two 25-mL portions of chloroform. Evaporate the combined chloroform extracts to dryness. Add 10 mL of ether, evaporate again, and dry at 105° for 2 h.

**Acceptance criteria:** The IR absorption spectrum of a potassium bromide dispersion of the residue so obtained exhibits maxima only at the same wavelengths as that of a similar preparation of [USP Thiopental RS](#).

#### • B. ~~IDENTIFICATION TESTS—GENERAL~~, [Sodium<191>](#).

**Analysis:** Ignite 500 mg.

**Acceptance criteria:** The residue meets the requirements.

#### • C.

**Sample:** 200 mg of Thiopental Sodium

**Analysis 1:** Dissolve the *Sample* in 5 mL of 1 N sodium hydroxide, and add 2 mL of lead acetate TS.

**Acceptance criteria 1:** A white precipitate is formed, and it gradually darkens when the mixture is boiled.

**Analysis 2:** Acidify the darkened mixture obtained from *Analysis 1* with hydrochloric acid.

**Acceptance criteria 2:** Hydrogen sulfide is evolved, and it is recognizable by its darkening of moistened lead acetate test paper held in the vapor.

### ASSAY

#### • PROCEDURE

**Solution A:** 4 g/L of sodium hydroxide

**Standard solution:** 5 µg/mL of [USP Thiopental RS](#) in *Solution A*

**Sample solution:** 5 µg/mL of Thiopental Sodium in *Solution A*

#### Instrumental conditions

**Mode:** UV

**Analytical wavelength:** 304 nm

**Cell:** 1 cm

**Blank:** *Solution A*

#### Analysis

**Samples:** *Standard solution*, *Sample solution*, and *Blank*

Calculate the percentage of thiopental sodium ( $C_{11}H_{17}N_2NaO_2S$ ) in the portion of Thiopental Sodium taken:

$$\text{Result} = (A_U/A_S) \times (C_S/C_U) \times (M_{r1}/M_{r2}) \times 100$$

$A_U$  = absorbance of the *Sample solution*

$A_S$  = absorbance of the *Standard solution*

$C_S$  = concentration of [USP Thiopental RS](#) in the *Standard solution* (µg/mL)

$C_U$  = concentration of Thiopental Sodium in the *Sample solution* (µg/mL)

$M_{r1}$  = molecular weight of thiopental sodium, 264.32

$M_{r2}$  = molecular weight of thiopental, 242.34

**Acceptance criteria:** 97.0%–102.0% on the dried basis

#### IMPURITIES

- [ORDINARY IMPURITIES \(466\)](#).

**Standard solution:** 9.2 mg/mL of [USP Thiopental RS](#) in methanol

**Sample solution:** 10 mg/mL of Thiopental Sodium in methanol

**Application volume:** 40 µL

**Eluant:** Toluene and methanol (85:15)

**Visualization:** 1

**Acceptance criteria:** Meets the requirements

#### SPECIFIC TESTS

- [Loss on Drying \(731\)](#).

**Analysis:** Dry at 80° for 4 h.

**Acceptance criteria:** NMT 2.0%

#### ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in tight containers.

- [USP REFERENCE STANDARDS \(11\)](#).

[USP Thiopental RS](#)

**Auxiliary Information** - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
THIOPENTAL SODIUM	<a href="#">Documentary Standards Support</a>	SM52020 Small Molecules 5
REFERENCE STANDARD SUPPORT	RS Technical Services <a href="mailto:RSTECH@usp.org">RSTECH@usp.org</a>	SM52020 Small Molecules 5

**Chromatographic Database Information:** [Chromatographic Database](#)

#### Most Recently Appeared In:

Pharmacopeial Forum: Volume No. PF 29(5)

**Current DocID:** GUID-EDB9A773-95A7-4E92-8F82-437A1707729C\_3\_en-US

**Previous DocID:** GUID-EDB9A773-95A7-4E92-8F82-437A1707729C\_1\_en-US

**DOI:** [https://doi.org/10.31003/USPNF\\_M82870\\_03\\_01](https://doi.org/10.31003/USPNF_M82870_03_01)

**DOI ref:** [dx11](#)